BRIEF published on 10/24/2024 at 09:35, 28 days ago QUANTRO Therapeutics and IMP Form Research Alliance for Drug Discovery Drug Discovery Cancer Therapy QUANTRO Therapeutics IMP Collaboration Transcription Factor
BRIEF published on 10/24/2024 at 09:35, 28 days ago QUANTRO Therapeutics et IMP forment une alliance de recherche pour la découverte de médicaments Thérapie Contre Le Cancer Découverte De Médicaments Thérapeutique QUANTRO Collaboration IMP Facteur De Transcription
PRESS RELEASE published on 10/24/2024 at 09:30, 28 days ago QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery QUANTRO Therapeutics partners with IMP to advance transcriptomic drug discovery. Strategic collaboration to explore transcription factors' functions for cancer therapies QUANTRO Therapeutics Transcription Factors IMP Transcriptomic Drug Discovery Cancer Therapies
BRIEF published on 08/06/2024 at 10:05, 3 months 14 days ago QUANTRO Therapeutics Secures Key Austrian Research Grant to Advance Platform Development Drug Discovery QUANTRO Therapeutics FFG Grant Transcriptomic Platform Multiplexing
BRIEF published on 08/06/2024 at 10:05, 3 months 14 days ago QUANTRO Therapeutics obtient une subvention de recherche autrichienne clé pour faire progresser le développement de la plateforme Découverte De Médicament QUANTRO Thérapeutique Bourse FFG Plateforme Transcriptomique Multiplexage
PRESS RELEASE published on 08/06/2024 at 10:00, 3 months 14 days ago QUANTRO Therapeutics secures important Austrian research grant to accelerate development of cutting-edge platform QUANTRO Therapeutics secures Austrian research grant to accelerate cutting-edge platform development, enabling multiplex target screening in drug discovery Drug Discovery QUANTRO Therapeutics Austrian Research Grant Transcriptomic Discovery Platform Multiplexing Capabilities
BRIEF published on 06/04/2024 at 23:12, 5 months 16 days ago QUANTRO Therapeutics Reaches Milestone in Collaboration with Boehringer Ingelheim Cancer Treatments R&D Collaboration Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors
BRIEF published on 06/04/2024 at 23:12, 5 months 16 days ago QUANTRO Therapeutics franchit une étape importante en collaboration avec Boehringer Ingelheim Boehringer Ingelheim QUANTRO Thérapeutique Traitements Contre Le Cancer Facteurs De Transcription Collaboration R&D
PRESS RELEASE published on 06/04/2024 at 23:07, 5 months 16 days ago QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments QUANTRO Therapeutics achieves key milestone in collaboration with Boehringer Ingelheim for first-in-class cancer treatments using proprietary technology Cancer Treatments Boehringer Ingelheim QUANTRO Therapeutics Transcription Factors R&D Program
PRESS RELEASE published on 04/04/2023 at 09:30, 1 year 7 months ago QUANTRO Therapeutics appoints Industry Expert Dr. Michael Bauer as Chief Executive Officer
Published on 11/21/2024 at 09:00, 46 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 11 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 21 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 46 minutes ago Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 46 minutes ago Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates
Published on 11/21/2024 at 08:59, 46 minutes ago Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 46 minutes ago Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 31 minutes ago EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 37 minutes ago KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024
Published on 11/21/2024 at 06:58, 2 hours 48 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 48 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 48 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 39 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 26 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
